FindTrial
Sign In

Use of antiviral drugs in breast cancer

Repurposing of Antiviral Drugs Targeting Lysine Demethylase 5B [KDM5B] Oncogene in Breast Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/08/020604
Enrollment
50
Registered
2019-08-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50- Malignant neoplasm of breast

Interventions

None listed

Sponsors

Dr T M A Pai Fellowship
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Newly diagnosed female breast cancer patients. Patients scheduled for Modified Radical Mastectomy (MRM) or Breast Conservative Surgery (BCS). Patients who are willing to give informed consent.

Exclusion criteria

Exclusion criteria: Vulnerable patients HIV, TB, Hepatitis positive patients.

Design outcomes

Primary

MeasureTime frame
KDM5B Gene Expression in Indian Breast cancer patientsTimepoint: 2 years—

Secondary

MeasureTime frame
In vitro and In vivo analysis of selected drug molecules targeting KDM5B oncogeneTimepoint: 3 years—

Countries

India

Contacts

Public ContactDr Mahadev Rao

Manipal Academy of Higher Education

mahadev.rao@manipal.edu

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026